Identity and synonyms
Thymalin, thymulin and thymosin α1 are distinct entities; catalog slash-labels are unresolved.
Mixture · Mixture or extract
Detailed molecular class: Thymus peptide mixture
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Immune-cell signaling effects studied; mixture composition matters.
Evidence and critical reading
Reported scientific and empirical uses
Aging research · Immune modulation and inflammation
Thymus-derived mixture, distinct from thymulin and thymosin alpha-1.
Human evidence
A comparative severe-COVID report exists; randomization and causal mortality benefit were not established from the retrieved abstract.
Preclinical evidence
THP-1 inflammatory-cell experiments.
Critical reading and limitations
Cell experiments and a severe-COVID comparison exist; the abstract does not establish causal mortality benefit.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human safety, contraindications and interactions are not adequately established for the catalog product. Missing reports are not evidence of safety.
Extract composition/quality matter; do not infer equivalence among brands or catalog powders.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Thymalin · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
The page treats Thymalin as a Thymulin synonym; that equivalence is not adopted to assign regimen or structure. · manual01 · Page 162
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID35408963
Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E.
October 16, 2026
- PMID36169363
Kuznik BI, Shapovalov KG, Smolyakov YN, Lukyanov SA, Tereshkov PP, Kazantseva LS, Linkova NS.
October 16, 2026
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026